SUBSCRIBE
SUBSCRIBE
News   Business

Incyte Corporation Arthritis Drug Shows Promise; Positive Phase 2 Data Triggers $30 Million Milestone from Eli Lilly and Company

May 6, 2010 | 
1 min read
Reuters -- Biotechnology firm Incyte Corp said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective.
Alliances Clinical research Phase 2
Eli Lilly and Company Incyte
MORE ON THIS TOPIC
Fashionable halftones collage. Startup business concept,fast business startup. Trendy modern retro illustration in bright trendy colors. Strategic planning concept and business success. Vector illustration
Rare diseases
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
March 12, 2026
 · 
2 min read
 · 
Tristan Manalac
Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.
Clinical research
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders
March 12, 2026
 · 
3 min read
 · 
Tristan Manalac
Businessman carrying big bag of money moving forward
C-suite
J&J, AbbVie CEOs See Pay Spike to More Than $30M
March 12, 2026
 · 
1 min read
 · 
Tristan Manalac
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker